Carisma Therapeutics (CARM) said Sunday that new preclinical data showed the potential of the company's engineered macrophages in multiple liver fibrosis models.
Results of the study showed that the engineered macrophages significantly reduced liver fibrosis and hepatic stellate cell activation. The engineered macrophages were also well tolerated in the study, the company said.
The company anticipates to nominate a development candidate for its liver fibrosis program in Q1 2025.
Price: 1.0407, Change: -0.01, Percent Change: -0.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments